Souhaitez-vous accéder aux communiqués récents ?

Animal owners may think they know what happens during a veterinary visit — but  a new global survey of 1,000+ veterinarians across 51 countries shows there is far more going on than meets the...

Not intended for US and UK media Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) are life-threatening, progressive lung conditions that require early and sustained...

Not intended for UK and US media Therapy approved based on Phase Ib Beamion LUNG-1 trial data, demonstrating robust efficacy (75.7% objective response rate) in treatment-naïve patients1Expedited...

Not intended for US and UK media New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS® (zongertinib tablets) as an initial treatment option in HER2...

Not intended for UK and US audiences JASCAYD® (nerandomilast) now approved by Japan’s MHLW for the treatment of adults with idiopathic pulmonary fibrosis and adults with progressive pulmonary...

Boehringer and Immunitas Therapeutics partner on a preclinical antibody program aimed at delivering more durable inflammatory disease control.

Eko Vet+TM | CANINEBEAT® AI helps veterinarians detect, visualize, and grade heart murmurs in dogs that can otherwise go undetectedThe CANINEBEAT® AI algorithm detects heart murmurs associated with...

In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight...

Boehringer is expanding its global Computational Innovation footprint with a new center dedicated to AI and machine learning (ML) in the UKEstablishing a presence in King’s Cross, London, places...

This press release is not intended for US or UK media. Ingelheim, Germany and Ridgefield, Conn. Boehringer Ingelheim today announced that The New England Journal of Medicine (NEJM) published results...